Biomea Fusion stock soars on early-stage diabetes data
Redwood City, CA-based Biomea Fusion saw about a 50% increase in its stock today after revealing early data for its covalent menin inhibitor, BMF-219, for the treatment of type 2 diabetes.
Data from two cohorts enrolled in the Phase II portion of its ongoing Phase I/II clinical study showed potential for the inhibitor to “release the brakes” of “regeneration, reactivation, and preservation” of beta cells, Biomea reported. Beta cells have to work harder in people with type 2 diabetes in order to produce enough insulin to lower blood sugar levels, leading to the loss or weakening of the cells.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters